The NIH Microphyiological Systems Program: In Vitro 3D Models for Safety and Efficacy Studies
Danilo Tagle,
Associate Director for Special Initiatives,
National Institutes of Health
Approximately 30% of drugs have failed in human clinical trials due to
adverse reactions despite promising pre-clinical studies, and another
60% fail due to lack of efficacy. A number of these failures can be
attributed to poor predictability of human response from animal and 2D
in vitro models currently being used in drug development. To address
this challenges in drug development, the NIH Tissue Chips or
Microphysiological Systems program is developing alternative innovative
approaches for more predictive readouts of toxicity or efficacy of
candidate drugs. Tissue chips are bioengineered 3D microfluidic
platforms utilizing chip technology and human-derived cells and tissues
that are intended to mimic tissue cytoarchitecture and functional units
of human organs and systems. In addition to drug development, these
microfabricated devices are useful for modeling human diseases, and for
studies in precision medicine and environment exposures. Presentation
will elaborate in the development and utility of microphysiologicals
sytems and in the partnerships with various stakeholders for its
implementation.
|
|
